Abbott Laboratories has filed a patent for an integrated analyte monitoring system and on-body patch pump with multiple cannulas and a sensor combination. The system includes a patch pump worn on the skin, a reservoir for insulin, a cannula for fluid path establishment, a processor, power supply, transmitter, and controller for insulin delivery control. GlobalData’s report on Abbott Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Abbott Laboratories, NSAID cancer drugs was a key innovation area identified from patents. Abbott Laboratories's grant share as of January 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Integrated insulin delivery system with patch pump and sensor
See Also:
A newly filed patent (Publication Number: US20240033429A1) describes an innovative insulin delivery system in the form of a patch pump designed to be worn on the skin surface of a user. The system includes a housing with an adhesive patch for attachment, a reservoir for storing insulin, a cannula for subcutaneous insertion, a processor for insulin control and cannula insertion, a power supply, and a transmitter for wireless communication with a controller. The controller, equipped with an input unit, output unit, and user interface, communicates with the patch pump to manage insulin delivery and cannula insertion, allowing for personalized and efficient insulin administration.
Furthermore, the system incorporates features such as an insertion mechanism with a spring-driven needle, a mobile phone controller option, the ability to deliver insulin based on programmed profiles or bolus dosages, and integration with a glucose sensor for real-time monitoring. The patch pump also includes a self-sealing septum port, an audible alert system, and a leakage sensor for enhanced safety and convenience. With a cannula designed for up to four days of insulin delivery, this on-body patch pump offers a comprehensive and user-friendly solution for individuals requiring continuous insulin therapy. Overall, the patent outlines a sophisticated insulin delivery system that combines cutting-edge technology with user-centric design to improve the management of diabetes and enhance the quality of life for patients.
To know more about GlobalData’s detailed insights on Abbott Laboratories, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
